Fingerprint
Dive into the research topics of 'PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer
Chang Ching Lin, Tsung Cheng Chang, Yunguan Wang, Lei Guo, Yunpeng Gao, Emmanuel Bikorimana, Andrew Lemoff, Yisheng V. Fang, He Zhang, Yanfeng Zhang, Dan Ye, Isabel Soria-Bretones, Alberto Servetto, Kyung Min Lee, Xuemei Luo, Joseph J. Otto, Hiroaki Akamatsu, Fabiana Napolitano, Ram Mani, David W. Cescon
- ML-Lab Mendell
- Molecular Biology
- Biochemistry
- Pathology
- Pathology
- PA-Lab Mani
- Urology - Adult
- Urology
- Pediatrics
- Pediatric Residency
- Peter O'Donnell Jr. School of Public Health
- SPH-Data Sciences in Precision
- Bioinformatics
- Bioinformatics
- Molecular Biology
- Simmons Comprehensive Cancer Center
- Ctr-Simmons Compr. Cancer
- Simmons Comprehensive Cancer Center - Administration - Directors Office - Administration
Research output: Contribution to journal › Article › peer-review
1
Scopus
citations